Achieve Pricing Flexibility & Accuracy in the Face of the IRA

The life sciences industry has always been faced with a complex process that is prone to errors when forecasting gross to net sales. There are many variables that need to be considered when arriving at net sales including rebates, Medicare rebates, chargebacks, returns, admin fees, and more. Ineffective gross-to-net planning leads to auditing and compliance repercussions, an inability to verify pricing adjustments, and insufficient systems and procedures. Now life science companies are additionally coming head-to-head with the impacts arising from the Inflation Reduction Act including negotiations with Medicare & Medicaid as well as inflation considerations. In today’s BrightTALK, we show how organizations can leverage the Anaplan platform to achieve pricing flexibility & accuracy in the face of the Inflation Reduction Act.